Why It Matters

Memantine is FDA-approved for Alzheimer’s disease—not ADHD. So why is it even in the conversation?

Because ADHD isn’t just a dopamine problem. Increasingly, research points to glutamate dysregulation—essentially too much “background noise” in brain signaling.

Memantine works on that system by blocking NMDA receptors, leading to reduced excitatory “noise”. This raises a compelling question:

Can a medication designed for cognitive decline help sharpen attention and executive function?

What the Research Shows

The evidence is limited, but intriguing:

A small 2019 randomized controlled trial (n=40) found that memantine significantly improved inattention, impulsivity, and emotional regulation compared to placebo over 6 weeks.
Earlier open-label data (Surman et al., 2013) showed meaningful reductions in overall ADHD symptoms & improvements in working memory and executive function
Adjunctive data (Biederman et al., 2017) suggest possible added benefit on executive function when combined with stimulants—but sample sizes were very small.Important context:

Important context: Memantine is not FDA-approved for ADHD (similar to alpha-2 agonists in adults), and the evidence base remains small.

Key Points / Practical Takeaways

Originally developed for Alzheimer’s disease, now explored off-label in ADHD
Works via glutamate modulation, not dopamine
Non-stimulant → effects tend to build gradually
May help with executive function and cognitive control
Evidence is early and limited

My Take

I think of memantine as a “noise regulator”, not a performance enhancer or stimulant alternative. It’s more like a way to quiet excess signaling, allowing the prefrontal cortex to function more efficiently.

In practice, this is not a first-line option.

But in the right patient—especially those who don’t tolerate or fully respond to standard treatments—it can be an interesting, mechanism-driven option. Still, we’re early here, and it remains a thoughtful off-label use—not a proven solution.

If you're seeking evaluation or treatment for adult ADHD in the Bay Area, learn more about our approach here.

Sources

Biederman J, Fried R, Tarko L, et al. Memantine in the Treatment of Executive Function Deficits in Adults With ADHD. Journal of Attention Disorders. 2017;21(4):343-352. doi:10.1177/1087054714538656.

Mohammadzadeh S, Ahangari TK, Yousefi F. The Effect of Memantine in Adult Patients With Attention Deficit Hyperactivity Disorder. Human Psychopharmacology. 2019;34(1):e2687. doi:10.1002/hup.2687.

Surman CB, Hammerness PG, Petty C, et al. A Pilot Open Label Prospective Study of Memantine Monotherapy in Adults With ADHD. The World Journal of Biological Psychiatry : The Official Journal of the World Federation of Societies of Biological Psychiatry. 2013;14(4):291-8. doi:10.3109/15622975.2011.623716.